CAJ | 학술논문

背景与目的:文献研究表明,多西他赛联合顺铂、氟尿嘧啶对晚期胃癌及胃食管贲门癌有效.本研究旨在评价多西他赛联合奈达铂、氟尿嘧啶(DNF方案)治疗晚期食管癌的临床疗效和毒副反应.方法:DNF方案治疗43例食管癌患者.具体用法:多西他赛75 ms/m~2第1天静脉滴注60 min;奈达铂100 mg/m~2第1天静脉滴注3 h;醛氢叶酸钙200 mg/m~2,第1天静脉滴注2 h,随后氟尿嘧啶375 ms/m~2静脉推注10 min,再以氟尿嘧啶2.6 s/m~2持续泵入46 h.21 d为一周期,每2周期按WHO疗效评价标准评价疗效,所有患者至少接受2周期化疗.结果:43例患者共接受144个周期的化疗,所有患者均可评价疗效.完全缓解2例(4.65%),部分缓解25例(58.14%),稳定9例(20.93%),进展7例(16.28%),总有效率为62.79%,中位疾病进展时间201 d,中位生存时间310 d.3～4度不良反应主要包括9例(20.93%)粒细胞减少(其中2例伴发热),3例(6.98%)血小板减少,4例(9.30%)恶心呕吐.化疗相关性死亡1例.结论:多西他赛联合奈达铂、氟尿嘧啶方案治疗晚期食管癌疗效较好,毒性可以接受,值得临床应用及进一步大样本、多中心研究.
배경여목적:문헌연구표명,다서타새연합순박、불뇨밀정대만기위암급위식관분문암유효.본연구지재평개다서타새연합내체박、불뇨밀정(DNF방안)치료만기식관암적림상료효화독부반응.방법:DNF방안치료43례식관암환자.구체용법:다서타새75 ms/m~2제1천정맥적주60 min;내체박100 mg/m~2제1천정맥적주3 h;철경협산개200 mg/m~2,제1천정맥적주2 h,수후불뇨밀정375 ms/m~2정맥추주10 min,재이불뇨밀정2.6 s/m~2지속빙입46 h.21 d위일주기,매2주기안WHO료효평개표준평개료효,소유환자지소접수2주기화료.결과:43례환자공접수144개주기적화료,소유환자균가평개료효.완전완해2례(4.65%),부분완해25례(58.14%),은정9례(20.93%),진전7례(16.28%),총유효솔위62.79%,중위질병진전시간201 d,중위생존시간310 d.3～4도불량반응주요포괄9례(20.93%)립세포감소(기중2례반발열),3례(6.98%)혈소판감소,4례(9.30%)악심구토.화료상관성사망1례.결론:다서타새연합내체박、불뇨밀정방안치료만기식관암료효교호,독성가이접수,치득림상응용급진일보대양본、다중심연구.
Background and Objective:Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma.This study was to evaluate the efficacy and toxicity of docetaxeI plus nedaptatin and 5-fluorouracil (DNF regimen)in treating advanced esophageal carcinoma.Methods:Fortythree patients with pathologically confirmed advanced esophageal carcinoma treated by DNF regimen:intravenous infusion of docetaxel(75 mg/m~2)over 1 h,intravenous infusion of nedaplatin(1 00 mg/m~2)over 3 h,intravenous infusion of leucovorin(CF,200 mg/m~2)over 2 h,intravenous injection of 5fluorouracil(375 mg/m~2)over 10 min,followed by a 46-hour infusion of 5fluorouracil(2.6 g/m~2).The cycle was repeated every three weeks.Treatment efficacy was evaluated every two weeks according to the WHO standards.All patients received at least two cycles of chemotherapy.Results:Patients received a total of 144 cycles of treatment,and all were evaluable for efficacy and toxicity.Of the 43 patients,2(4.65%)achieved complete response(CR),25(58.14%)achieved partial response(PR),9 (20.93%)had stable disease(SD),and 7(16.28%)had progressive disease(PD).The overall response rate was 62.8%.The median time-toprogression(TTP)was 201 days and the median survival time(MST)was 310 days.Grade Ⅲ/Ⅳ adverse events mainly included neutropenia (20.93%),febrile neutropenia(4.65%),thrombocytopenia(6.98%)and vomiting(9.30%).One patient died of grade Ⅳ thrombocytopenia.Conclusion:DNF regimen is effective for and well tolerated by patients with advanced esophageal carcinoma.